Quantitative protein determination for CYP induction via LC-MS/MS

Proteomics

Volumn 11, Issue 1, 2011, Pages 33-41

  Williamson, Brian L ^a   Purkayastha, Subhasish ^a   Hunter, Christie L ^a   Nuwaysir, Lydia ^a   Hill, James ^b   Easterwood, LaHoma ^b   Hill, Jeanette ^b  

^a MDS SCIEX   (Canada)

^b Life Technologies Corporation   (United States)

Author keywords

Cell biology; ESI MS MS; LC; Liver proteins; Protein induction; Proteomics methods

Indexed keywords

CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2B6; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; LIVER PROTEIN; PHENOBARBITAL;

ARTICLE; CONTROLLED STUDY; ELECTROSPRAY MASS SPECTROMETRY; ENZYME ASSAY; ENZYME INDUCTION; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; LIQUID CHROMATOGRAPHY; LIVER MICROSOME; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS;

CELLS, CULTURED; CHROMATOGRAPHY, LIQUID; CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; MICROSOMES, LIVER; PROTEIN ISOFORMS; PROTEOMICS; TANDEM MASS SPECTROMETRY;

EID: 78650346164     PISSN: 16159853     EISSN: 16159861     Source Type: Journal    
DOI: 10.1002/pmic.201000456     Document Type: Article

References (27)

1. Denisov, I. L., Makris, T. M., Sligar, S. G., Schlichting, I., Structure and chemistry of cytochrome P450. Chem. Rev. 2005, 105, 2253-2277.
2. FDA, Draft Guidance for Industry - drug interaction studies: study design, data analysis, and implications for dosing and labeling. Food and Drug Administration Publication 2006.
3. LeCluyse, E., Pregnane X receptor: molecular basis for species differences in CYP3A induction by xenobiotics. Chem. Biol. Interact. 2001, 134, 283-289.
4. LeCluyse, E., Madan, A., Hamilton, G., Carroll, K. et al., Expression and regulation of cytochrome P450 enzymes in primary cultures of human hepatocytes. J. Biochem. Mol. Toxicol. 2000, 14, 177-188.
5. Madan, A., Graham, R. A., Carroll, K. M., Mudra, D. R. et al., Effects of prototypical microsomal enzyme inducers on cytochrome P450 expression in cultured human hepatocytes. Drug Metab. Dispos. 2003, 31, 421-431.
6. Wang, H., LeCluyse, E., Role of orphan nuclear receptors in the regulation of drug metabolizing enzymes. Clin. Pharmacokinet. 2003, 42, 1331-1357.
7. Chu, V., Einolf, H. J., Evers, R., Kumar, G. et al., In vitro and in vivo induction of cytochrome P450: A survey of the current practices and recommendations: A pharmaceutical research and manufacturers of America perspective. Drug Metab. Dispos. 2009, 37, 1339-1354.
8. Anderson, L., Seilhamer, J., A comparison of selected mRNA and protein abundance in human liver. Electrophoresis 1997, 18, 533-537.
9. Chen, G., Gharib, T. G., Huang, C. C., Taylor, J. M. G. et al., Discordant protein and mRNA expression in lung adenocarinomas. Mol. Cell. Proteomics 2002, 1, 304-313.
10. Huber, M., Bahr, I., Kratzschmar, J. R., Becker, A. et al., Comparison of proteomic and genomic analysis of the human breast cancer cell line T47D and the antiestrogen-resistant derivative T47D-r. Mol. Cell. Proteomics 2004, 3, 43-55.
11. Alterman, M. A., Kornilayev, B., Duzhak, T., Yaovlev, D., Quantitative analysis of Cytochrome P450 isozymes by means of unique isozyme-specific tryptic peptides: A proteomic approach. Drug Metab. Dispos. 2005, 33, 1399-1407.
12. Jenkins, R. E., Kitteringham, N. R., Hunter, C. L., Webb, S. et al., Relative and absolute quantitative expression profiling of cytochromes P450 using isotope-coded affinity tags. Proteomics 2006, 6, 1934-1947.
13. Duan, X., Chen, X., Yang, Y., Zhong, D., Precolumn derivatization of cysteine residues for quantitative analysis of five major P450 isoenzymes by liquid chromatography/tandem mass spectrometry. Rapid Commun. Mass Spectrom. 2007, 21, 3234-3244.
14. Sutton, C., Sutherland, M., Shnyder, S., Patterson, L., Improved preparation and detection of cytochrome P450 isoforms using mass spectrometric methods. Proteomics 2010, 10, 327-331.
15. Lane, C. S., Wang, Y., Betts, R., Griffiths, W. J., Patterson, L. H., Comparative cytochrome P450 proteomics in the livers of immunodeficient mice using O18 stable isotope labeling. Mol. Cell. Proteomics 2007, 6, 953-962.
16. Seibert, C., Davidson, B. R., Fuller, B. J., Patterson, L. H. et al., Multiple approaches to the identification and quantitation of cytochrome P450 in human liver tissue by mass spectrometry. J. Proteome Res. 2009, 8, 1672-1681.
17. Wang, W. Z., Wu, J. Q., Dennison, J. B., Bridges, A. S. et al., A gel free MS-based quantitative proteomic approach accurately measures cytochrome P450 protein concentrations in human liver microsomes. Proteomics 2008, 8, 4186-4196.
18. Anderson, L., Hunter, L., Quantitative mass spectrometric multiple reaction monitoring assays for major plasma proteins. Mol. Cell. Proteomics 2006, 5, 573-588.
19. Hesse, L. M., Sakai, Y., Vishnuvardhan, D., Li, A. P., von Moltke, L. L., Greenblatt, D. J., Effect of bupropion on CYP2B6 and CYP3A4 catalytic activity, immunoreactive protein and MRNA levels in primary human hepatocytes: comparison with rifampicin. J. Pharm. Pharmacol. 2003, 55, 1229-1239.
20. Zhang, J. G., Ho, T., Callendrello, A. L., Crespi, C. L., Stresser, D. M., A multi-endpoint evaluation of cytochrome P450 1A2, 2B6 and 3A4 induction response in human hepatocycte cultures after treatmeant with beta-naphthoflavone, phenobarbital and rifampcin. Drug Metab. Lett. 2010, Jun 28, Epub ahead of print.
21. Burk, O., Koch, I., Raucy, J., The induction of cytochrome P450 3A5 (CYP3A5) in the human liver and intestine is mediated by the xenobiotic sensors pregnane X receptor (PXR) and constitutively activated receptor (CAR). J. Biol.. Chem. 2004, 279, 38379-38385.
22. Rodriguez-Antona, C., Jover, R., Gomez-Lechon, M. J., Castell, J. V., Quantitative RT-PCR measurement of human cytochrome P-450s: application to drug induction studies. Arch. Biochem. Biophys. 2000, 376, 109-116.
23. Rae, J. M., Johnson, M. D., Lippman, M. E., Flockhart, D. A., Rifampin is a selective, pleiotropic inducer of drug metabolism genes in human hepatocytes: studies with cDNA and oligonucleotide expression arrays. J. Pharmacol. Exp. Ther. 2001, 299, 849-857.
24. Jounaidi, Y., Guzelian, P. S., Maurel, P., Vilarem, M. J., Sequence of the 5'-flanking region of CYP3A5: comparative analysis with CYP3A4 and CYP3A7. Biochem. Biophys. Res. Commun. 1994, 205, 1741-1747.
25. Schuetz, J. D., Schuetz, E. G., Thottassery, J. V., Guzelian, P. S. et al., Identification of a novel dexamethasone responsive enhancer in the human CYP3A5 gene and its activation in human and rat liver cells. Mol. Pharmacol. 1996, 49, 63-72.
26. Solus, J. F., Arietta, B. J., Harris, J. R., Sexton, D. P. et al., Genetic variation in eleven phase I drug metabolism genes in an ethnically diverse population. Pharmacogenomics 2004, 5, 895-931.
27. Lang, T., Klein, K., Fischer, J., Nüssler, A. K. et al., Extensive genetic polymorphism in the human CYP2B6 gene. Pharmacogenomics 2001, 11, 399-415.